Please assess the completion status of the following clinical trial:

Trial Title: A Study of PF-06438179 (Infliximab-Pfizer) and Infliximab in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (REFLECTIONS B537-02).

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Diagnosis of rheumatoid arthritis based on 2010 ACR/EULAR criteria for at least 4 months.~At least 6 tender (of 68 assessed) and 6 swollen (of 66 assessed) joints at screening and baseline.~HS-CRP equal or greater than 10 mg/L.~Must have received methotrexate for at least 12 weeks and be on a stable dose for at least 4 weeks.~Exclusion Criteria:~Evidence of untreated or inadequately treated latent or active TB.~Evidence or history of moderate or severe heart failure (NYHA Class III/IV)~Infection requiring hospitalization or parenteral antimicrobial therapy judged clinically significant by the investigator within 6 months prior to first dose of study drug.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PF-06438179 (Type: EXPERIMENTAL): None
- Infliximab (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).